Monday, May 25, 2015

Yoma downgraded to 'reduce', target cut to 46 cents by CIMB

Stock Name: Yoma Strategic
Research House: CIMBPrice Call: SELLTarget Price: 0.46

SINGAPORE (May 25): CIMB has downgraded Yoma Strategic Holdings to "reduce" from "hold" and cut its price target to 46 cents from 57 cents after lowering its core earnings per share estimates by 64.3% for FY2016 and 25.6% for FY2017.

"Yoma's real estate business is expected to face headwinds in the next 12 months due to the increasing competition and wait-and-see sentiment related to the uncertainty surrounding the Myanmar general election towards the end of 2015," CIMB analysts Roy Chen and William Tng wrote in a note.

Thai Beverage kept at 'add' by CIMB with unchanged target price of 87 cents

Stock Name: ThaiBev
Research House: CIMBPrice Call: BUYTarget Price: 0.87

SINGAPORE (May 25): The successful traction of new products might be a re-rating catalyst for Thai Beverage Public Company Limited, according to CIMB Research.

Under Vision 2020, the group aims to be a leader in beer in Thailand, but at the same time diversify revenue contributions away from alcohol and out of Thailand.

"The seeds are being sown. Beer is doing well," said CIMB research analysts Kenneth Ng and Jonathan Seow in a note last Friday.

For now, CIMB has kept its "add" rating for the stock with an unchanged target price of 87 cents.

Friday, May 22, 2015

Lian Beng Group gets 'buy' call, 72.5-cent target from UOB Kay Hian

Stock Name: Lian Beng
Research House: UOB KayHianPrice Call: BUYTarget Price: 72.50

SINGAPORE (May 22): UOB Kay Hian has started coverage on Lian Beng Group with a "buy" rating and price target of 72.5 cents.

With a projected FY2016 dividend yield of 4.7%, growing recurring income driven by rental from investment properties, and nearly $90 million of development profits yet to be recognised, Lian Beng offers "good value" at its current price, according to UOB Kay Hian analyst Loke Chunying.

Thursday, May 21, 2015

Raffles Medical upgraded to 'buy', target raised to $5.10 by Maybank

Stock Name: Raffles Medical
Research House: Maybank Kim EngPrice Call: BUYTarget Price: 5.10

SINGAPORE (May 21): Maybank Kim Eng has upgraded Raffles Medical Group to "buy" from "hold" and raised its price target to $5.10 from $3.89.

The revised target takes into account future contributions from the company's upcoming hospital in Shanghai.

"Raffles Medical can be considered an early entrant into China's private hospital segment, as most foreign investors only operate clinics and medical centres currently," Maybank Kim Eng analyst John Cheong wrote in a note today.

Ezion kept at 'buy' with TP of $1.50 by DBS after clearing the air with analysts

Stock Name: Ezion
Research House: DBS VickersPrice Call: BUYTarget Price: 1.50

SINGAPORE (May 21): DBS Group Research is keeping its "buy" call on Ezion Holdings with a target price of $1.50.

In a report out today, DBS said it now has a fuller picture of the dispute after Ezion hosted an analyst briefing to address the dispute with partner Atlantic Marine Services BV (AMS).

"Arguments seem logical. We continue to give Ezion the benefit of the doubt. The stock has fallen 12% within a week. Maintain BUY and TP of S$1.50 (8x FY15 PE)," wrote analyst Ho Pei Hwa.

Hyflux kept at 'hold' with 96 cents fair value by OCBC

Stock Name: Hyflux
Company Name: HYFLUX LTD
Research House: OCBCPrice Call: HOLDTarget Price: 0.96

SINGAPORE (May 21): OCBC Investment Research is maintaining its "hold" call on water company Hyflux with a fair value of 96 cents.

In a report out today, analysts Carey Wong and Andy Wong noted that Hyflux has been appointed the designer and technology provider for a potable water plant at Pun Hlaing Gold Estate in Myanmar.

The project, while small with a treatment capacity of 1,000 cubic metres per day, could open more opportunities for Hyflux and Yoma to cooperate on future projects in Myanmar.

Pun Hlaing Gold Estate is developed by Yoma Strategic Holdings.

Wednesday, May 20, 2015

iFAST started at 'buy' with target price of $1.31 by OCBC

Stock Name: IFAST
Research House: OCBCPrice Call: BUYTarget Price: 1.60

SINGAPORE (May 20): OCBC Research is initiating coverage on iFAST Corp with a "buy" call and a target price of $1.60.

In a report out today, OCBC likes iFAST for its unique proposition as an Internet-based investment platform as well as new initiatives to drive growth from 2H15.

"We believe iFAST offers investors a unique investment proposition as a direct proxy to the wealth management industry as well as an angle into digital finance," says analyst Lim Sue Lin.